The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries, most of which are in Africa. Under this agreement, Lilly has been supplying its active pharmaceutical ingredient for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Foghorn to discontinue independent development of FHD-286 with decitabine in AML
- Study confirms semaglutide link to increased, but ‘low,’ risk of NAION
- Eli Lilly’s Omvoh recommended by CHMP for approval in EU
- Arvinas down on investors’ read of Lilly data, says BTIG
- Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
